Updated:
Azitra
Azitra, incorporated in Delaware and headquartered in Connecticut, was founded in 2014 by Travis Whitfill and scientists from Yale University.
Azitra
Azitra, incorporated in Delaware and headquartered in Connecticut, was founded in 2014 by Travis Whitfill and scientists from Yale University. The company went public via an initial public offering in 2023, listing on the NYSE American under the ticker AZTR. The firm's foundational intellectual property was licensed from Yale, built on research into the skin microbiome and the engineering of non-pathogenic bacteria for therapeutic use. CEO Francisco Salva leads the company, with co-founder Whitfill serving as Chief Operating Officer. The company's lead candidate, ATR-12, is an engineered strain of Staphylococcus epidermidis designed to deliver functional lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein for Netherton syndrome, a severe genetic ichthyosis. ATR-12 received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Azitra also develops ATR-04 for the treatment of papulopustular rash associated with epidermal growth factor receptor (EGFR) inhibitors. The firm entered into a global strategic partnership with Bayer Consumer Care in 2023 for the development of microbiome-based skin care products. Azitra operates from a laboratory and office facility in Branford, Connecticut. As of its 2023 listing, the company remains pre-revenue, funding clinical development through public equity raises. In September 2023, the company reported positive safety and preliminary efficacy data from its Phase 1b trial of ATR-12 in Netherton syndrome patients (per the firm, September 2023). In 2024, Azitra secured additional financing through a registered direct offering to extend its cash runway into the second half of 2025, progressing toward a Phase 2 clinical trial for ATR-12. Azitra's core structural difference lies in its use of a native skin commensal—Staphylococcus epidermidis—as a living biotherapeutic. This contrasts with most skin gene therapy approaches that use viral vectors or recombinant proteins. Because S. epidermidis naturally colonizes the human epidermis without causing disease, the platform proposes a durable, self-renewing topical delivery system that avoids systemic exposure, potentially achieving efficacy with fewer systemic side effects than injectable biologics.
General information
Firm type
Asset Manager
Year founded
2014
Location
Region
North America
Country
United States
City
Branford
Corporate office
Branford, CT, United States
Principals
Francisco Salva
Chief Executive Officer
Travis Whitfill
Chief Operating Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Azitra?
Azitra is a publicly traded operating company, not an investment firm. No allocator invests in Azitra as an asset manager; institutional shareholders invest in a clinical-stage biotech. CEO Francisco Salva and the board of directors, not a chief investment officer, make capital allocation decisions. The company raised capital through an IPO in 2023 and subsequent registered direct offerings.
What is Azitra's core technology platform?
Azitra's platform uses genetically modified Staphylococcus epidermidis, a commensal skin bacterium, to produce and deliver therapeutic proteins directly on the skin. The bacteria are engineered to secrete missing or beneficial proteins for skin diseases. The lead candidate, ATR-12, expresses the LEKTI protein missing in Netherton syndrome patients. This live-biotherapeutic approach contrasts with traditional topical creams that deliver inactive ingredients or systemic biologics.
What is the status of Azitra's clinical pipeline?
The lead candidate ATR-12 completed a Phase 1b trial in Netherton syndrome in 2023 with positive safety and preliminary efficacy signals. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations. A Phase 2 trial is planned, with the company's cash runway extending into the second half of 2025 as of its 2024 financing. ATR-04, targeting EGFR inhibitor-induced rash, is in earlier stages of development. The firm also has a partnered program in consumer skin care with Bayer.
How does Azitra's approach differ from other dermatology biotechs?
Azitra uses a living skin commensal as a vehicle for localized, continuous protein delivery, eliminating the need for systemic administration or frequent reapplication. Most dermatologic biologics are systemic antibodies or interleukins with off-target immunogenicity risks; topical formulations of large proteins typically face poor stratum corneum penetration. By employing a bacterium that naturally resides on the skin, Azitra aims to overcome the delivery barrier while maintaining localized action. No other publicly traded biotech is using engineered S. epidermidis as a therapeutic chassis for protein deficiencies.
Does Azitra maintain philanthropic structures or separate foundations?
No philanthropic arm or separate foundation is disclosed in public filings. The company focuses its resources on clinical development. Any charitable giving by Azitra would flow through standard corporate donation programs, not a dedicated foundation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: